ADXN — ADDEX THERAPEUTICS LTD
As of Q2 2026, 1 SEC-registered investment managers reported holding ADXN (ADDEX THERAPEUTICS LTD) in their latest 13F filings, with a combined reported value of $268 across 47 shares. That is -84.4% by share count (-254 shares) versus the previous quarter, while reported value moved -85.8%. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 1 opened new positions, 1 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
ADXN is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
| Fund | Quarter | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|---|
| Citadel Advisors history | Q1 2025 | 11.74K | $86.18K | 0.00% | Reduce |
| Millennium Management history | Q3 2022 | 19.96K | $16.00K | 0.00% | New |
| Morgan Stanley history | Q1 2026 | 301 | $1.89K | 0.00% | Hold |
| JPMorgan Chase & Co history | Q2 2025 | 79 | $699 | 0.00% | New |
| UBS Group AG history | Q2 2026 | 47 | $268 | 0.00% | New |
| Renaissance Technologies history | Q4 2022 | 21.90K | $14 | 0.00% | Reduce |
New Positions (Q2 2026)
- UBS Group AG 47 sh · $268
Fully Exited (vs previous quarter)
- Morgan Stanley sold 301 sh · $1.89K
Fund Position History — shares by quarter (top 6 funds)
| Fund | Q3 2021 | Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q3 2023 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UBS Group AG | 13.00K | 17.30K | 2.81K | 7.95K | 7.03K | 14.53K | — | 74 | — | — | — | — | — | 1 | 156 | — | 47 |
| Morgan Stanley | — | — | — | — | — | — | — | — | 1.50K | 353 | 1.90K | 100 | 100 | — | 300 | 301 | — |
| Citadel Advisors | — | — | — | — | 12.80K | 41.38K | 34.38K | — | — | — | 12.08K | 11.74K | — | — | — | — | — |
| JPMorgan Chase & Co | — | — | — | — | — | — | — | — | — | — | — | — | 79 | — | — | — | — |
| Renaissance Technologies | — | — | — | — | 29.55K | 21.90K | — | — | — | — | — | — | — | — | — | — | — |
| Millennium Management | — | — | — | — | 19.96K | — | — | — | — | — | — | — | — | — | — | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details